The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index; 57 of the 170 sources its claims cite were checked for support.
Impact of the ONCOBIOME network in cancer microbiome research
Open accessAbstract
The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
30 Valid · 5 Not valid · 67 Not checked · 19 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“By contrast, fecal detection of oral taxa, species from the immunosuppressive Enterocloster genus or Hungatella hathewayi was associated with therapeutic resistance 36”
§ Impact of the ONCOBIOME network in cancer microbiome research > Pan-cancer meta-analysis
What the sources say
- Supportedcites [36] Thomas, A. M. et al. Gut oncomicrobiome signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 583–603 (2023). source
In “GOMS and prediction of response to ICIs,” the paper reports a stool-based analysis in which non-responder signatures included Enterocloster, Hungatella hathewayi, and the oral genera Streptococcus and Actinomyces. This supports the association with resistance to immune checkpoint inhibitors; it does not imply that the bacteria cause resistance. (LLM, conf=0.93)
plainstates an associationn = 808- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“revealed limited reproducibility of metastatic melanoma GOMS across distinct publicly available datasets 19,38”
§ Impact of the ONCOBIOME network in cancer microbiome research > Metastatic melanoma
What the sources say
- Supportedcites [19] McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022). source
The Discussion (page not available) says models trained on individual melanoma cohorts failed to predict response in other cohorts, citing cohort heterogeneity, while meta-analysis largely confirmed broader microbial associations. The Results, “Gut microbiome composition predicts clinical response” (page not available), likewise reports variable cross-cohort performance. This supports limited reproducibility of cohort-specific gut microbiome signatures, though the paper also reports improved prediction using pooled, batch-corrected data. (LLM, conf=0.90)
- Supportedcites [38] Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022). source
The Results section ('Limited reproducibility of response predictions across cohorts') reports that microbiome-based predictions of immunotherapy response had limited cross-cohort consistency, including across publicly available melanoma datasets. The Discussion likewise reports no taxonomic or functional microbiome biomarkers consistent across all datasets. (LLM, conf=0.91)
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of note, the frequency of apoptotic enterocytes detectable in the ileum (but not in the colon) correlated with favorable prognosis in patients with right colon cancer receiving oxaliplatin-based chemotherapy 30”
§ Impact of the ONCOBIOME network in cancer microbiome research > Diagnosis of gut dysbiosis: from GOMS to the TOPOSCORE
What the sources say
- Partly supportedcites [30] Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020). sourceExperimental — accuracy not yet measured
Our copy supports the ileum-versus-colon contrast and the direction of the association: apoptosis was induced by chemotherapy 'only in the crypts of ilea, but not in the villi, lamina propria or healthy colons adjacent to tumors' (Ileal apoptosis dictates the prognosis…, Fig. 1a,b), and higher cCasp3 density in ileal crypts segregated PFS (Fig. 1 log-rank P = 0.05 for ileum vs P = 0.20 for colon). However, the prognostic correlation is attributed to a different patient subset than the claim states: the main text says 'higher BASELINE levels of cCasp3 in ileal crypts (≥ median value) were associated with favorable prognosis in patients with stage IV pCC in univariate analyses (Fig. 1c)', and the Fig. 1c legend specifies 'patients with NONTREATED stage IV pCC from the validation cohort (ileum n = 18, colon n = 13)'. Thus the claim's qualifier 'receiving oxaliplatin-based chemotherapy' is not what the source reports, and the restriction to stage IV proximal (right) colon cancer is dropped; oxaliplatin preconditioning in the paper concerns the induction of ileal crypt apoptosis and its immunogenicity (mouse/avatar work), not the patient survival association. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“such as the genus Enterocloster”
- Also stated in: § Immunogenic versus tolerogenic microorganisms · plain
“H. hathewayi, which compromise the efficacy of ICB 29,30”
§ Impact of the ONCOBIOME network in cancer microbiome research > Immunogenic versus tolerogenic microorganisms
What the sources say
- Partly supportedcites [29] Yonekura, S. et al. Cancer induces a stress ileopathy depending on β-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis. Cancer Discov. 12, 1128–1151 (2022). sourceExperimental — accuracy not yet measured
Our copy supports the H. hathewayi component: in 'Significance of Intestinal Dysbiosis in Cancer' the authors gavaged tumor-bearing mice receiving anti-PD-1 mAb with Clostridia spp. associated with antibiotic- and tumor-induced immunosuppression, including C./Hungatella hathewayi and C. clostridioforme, and this 'significantly compromised the efficacy of the immunotherapy' (whereas Lactobacillus reuteri did not). However, the genus name Enterocloster never appears anywhere in our copy (searched: Enterocloster, Enterocloster bolteae/clostridioforme); the human data in 'The Gut Oncomicrobiome Signature of Patients with Cancer' list Clostridium boltae, C. citroniae, C. clostridioforme, C. asparagiforme, C. lavalense as overrepresented in patients with cancer, described as cancer/stress-ileopathy-driven dysbiosis rather than expansion during chronic inflammation, and the immunotherapy-compromising effect is shown only by murine gavage. So the Enterocloster attribution and the chronic-inflammation framing are not supported by this source. (LLM, conf=0.72)
- Partly supportedcites [30] Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020). sourceExperimental — accuracy not yet measured
Roberti et al. (2020) do support the generic part of the claim: in the 'Mechanisms underlying the priming of T FH cells with oxaliplatin' section they report that gavaging mice with tolerogenic commensals 'contrasting with P. clara or F. nucleatum that blunted the efficacy of the combination therapy' (OXA + anti-PD-1), and the Fig. 6h model in the Discussion ties Fusobacteriaceae/Prevotellaceae-dominated ileal microbiomes to poor αPD-1 efficacy. However, the specific taxa the citing sentence identifies — the genus Enterocloster and H. hathewayi — appear nowhere in our copy (searched: Enterocloster, Clostridium, hathewayi, enriched genera; the only Clostridia-related taxon named is Erysipeloclostridium ramosum, described as immunogenic/enriched in responders), nor is any expansion during chronic inflammation described; the work concerns ileal mucosa microbiota of proximal colon cancer patients and murine gavage/FMT models, not inflammation-driven outgrowth. So the identification of Enterocloster as an ICB-blunting bacterium is not attributable to this source. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Immunogenic versus tolerogenic microorganisms · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various F. prausnitzii SGBs are associated with favorable prognosis in patients diagnosed with several cancer types 23,24,56”
§ Impact of the ONCOBIOME network in cancer microbiome research > Immunogenic versus tolerogenic microorganisms
What the sources say
- Partly supportedcites [23] Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022). sourceExperimental — accuracy not yet measured
The Discussion ('Links between fecal Akk...' / DISCUSSION) does place Faecalibacterium prausnitzii within an Akk-associated community 'associated with a health or immunogenic status' and states that Faecalibacterium, Ruminococcus and Bifidobacterium 'were previously reported to be enriched in North-American, Japanese and South Korean patients with melanoma and NSCLC cancers and have favorable outcome' — but that cross-cancer point is explicitly credited to other works (refs 17,20,41,44), and this study's own cohort is advanced NSCLC only. The claim's species-genome-bin (SGB) resolution is not supported: in our copy SGBs are used solely for Akkermansia muciniphila (SGB9223/9224/9226/9228, M&M 'Human stool samples and metagenomics analyses'), and F. prausnitzii is absent from the outcome analysis, where the bacteria associated with prolonged or reduced survival are E. hallii, B. adolescentis, P. excrementihominis, I. butyriciproducens and C. innocuum ('Stratification of clinical outcome based on other components of the Akk-associated ecosystem'). So only the generic 'Faecalibacterium prausnitzii tracks with favorable outcome' element is in this source, not multiple F. prausnitzii SGBs across several cancer types. (LLM, conf=0.70)
- Could not verifycites [24] Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019). sourceExperimental — accuracy not yet measured
Our copy of Thomas et al. (2019, Nat Med) is a case-control diagnostic meta-analysis of colorectal cancer: the Results ('A panel of microbial biomarkers for CRC is reproducible across cohorts') report differential abundance of species such as F. nucleatum, S. moorei, P. asaccharolytica, P. micra, P. stomatis and control-associated Gordonibacter pamelae/Bifidobacterium catenulatum, with no survival or prognosis endpoint anywhere (searched: 'prognosis survival patient outcome follow-up', 'Faecalibacterium prausnitzii'). Faecalibacterium prausnitzii is not named in any passage, and the only 'species-level genome bin (SGB)' mention (Results, cutC variant section) refers to an unknown Lachnospiraceae SGB ID 3957, not to F. prausnitzii SGBs. The cited paper therefore does not address the claim's point, so it can neither confirm nor contradict it. (LLM, conf=0.72)
- Partly supportedcites [56] Bredon, M. et al. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13, 2374954 (2024). sourceExperimental — accuracy not yet measured
Our copy supports the prognostic part at species level: the Introduction (p. n/a) states 'Several other studies also identified that high F. prausnitzii level was associated with better response to ICI in multiple cancer types', lists baseline F. prausnitzii as a predictor of ICI response in hepatocellular carcinoma and NSCLC, and reports cross-cancer strain–response signatures (crediting Gunjur et al., ref 16); its own Results show higher F. prausnitzii abundance associated with better OS in advanced NSCLC and in one of two melanoma community types. What our copy does not support is the specific unit of the claim — 'various F. prausnitzii SGBs' (species-level genome bins): no passage in our copy mentions SGBs, and the paper profiles F. prausnitzii at species level with MetaPhlAn 4 (with strain-level resolution only when summarising another study). The melanoma OS signal is also conditional (absent in the pooled whole-population analysis and in the second community type), which the citing sentence's unqualified 'favorable prognosis' does not carry. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
67 more claims · 18 with their cited sources checked
Create a free account to see all 121 claims and to verify the 113 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The TOPOSCORE is one deliverable that was developed and validated by this project.200,207”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [207]
Citations
Cites
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 6×
“The rationale of this trial is based on preclinical work demonstrating that strain p2261 is particularly efficient in stimulating anticancer immune responses in avatar mice that would otherwise not respond to ICB 22,23 .”
InfluentialSelf-citationAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 6×
“…as adjuvant signals mediated by microbial-associated molecular patterns acting on pattern recognition receptors expressed on host immune cells 30,48,49 ; molecular mimicry between microbial and tumor-associated antigens, resulting in cross-reactive T cell responses 55 ; the migration of immune…”
InfluentialSelf-citationThe human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Self-citationPlovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationFecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 2×
“…of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5 as well as the early success of fecal microbial transplantation (FMT) and the probiotic Clostridium butyri-cum CBM 588 in patients with cancer undergoing treatment 6–10 .”
Self-citationFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Cited by
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationTudorache, M., Treteanu, A. R., Pîrcălăbioru, G. G., Lixandru-Petre, I.-O., Bolocan, A., & Andronic, O. (2025) · Cancers · doi:10.3390/cancers17142294 · Cited by 20
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Silva, C. A. C., Machaalani, M., Saliby, R. M., Zhong, C., Xie, W., Pasolli, E., Piccinno, G., Dalban, C., Fidelle, M., Meurisse, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04067-x · Cited by 17
Self-citationBlanco, J. R., del Campo, R., Ortiz, J. A., Olmos, M. L., & Carnero, A. (2025) · Cells · doi:10.3390/cells14221813 · Cited by 14
Zhang, N., Ren, Y., & Xu, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1627949 · Cited by 14
Metadata
- Authors
- Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., Boleij, A., Bol, K., Brusselaers, N., Budinska, E., Caldas, C., Cordero, F., Cremolini, C., Daillère, R., Denkert, C., Durand, S., Ehrlich, S., Eisinger, F., Elkrief, A., Fall, K., Felder, B., Ferrere, G., Fidelle, M., Gaborit, J., Gariboldi, M., Guindo, C. O., Iebba, V., Lehtio, J., Martineau, M., Messaoudene, M., Monville, F., Naccarati, A., Pardini, B., Pinto, F., Piccinno, G., Pizzato, E., Popovici, V., Rachid, M. H., Tarallo, S., Schuler-Thurner, B., Schuler, G., Szallasi, Z., Sow, C., Trinchieri, G., Trochon, J.-J., Zeller, G., Segata, N., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Goethe University Frankfurt (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Karolinska Institutet (SE)
- University of Trento (IT)
- UniCancer Group (FR)
- Radboud University Medical Center (NL)
- University of Antwerp (BE)
- Masaryk University (CZ)
- University of Cambridge (GB)
- University of Turin (IT)
- University of Pisa (IT)
- Philipps University of Marburg (DE)
- King's College London (GB)
- Institut Gustave Roussy (FR)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Italian institute for Genomic Medicine (IT)
- Leiden University (NL)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Zitvogel, Laurence
- Derosa, Lisa
- Routy, Bertrand
- Loibl, Sibylle
- Heinzerling, Lucie
- de Vries, I. Jolanda M.
- Engstrand, Lars
- Boleij, Annemarie
- Bol, Kalijn
- Caldas, Carlos
- Ehrlich, Stanislav
- Eisinger, François
- Elkrief, Arielle
- Fall, Katja
- Messaoudene, Meriem
- Piccinno, Gianmarco
- Popovici, Vlad
- Rachid, Maan Haj
- Sow, Cissé
- Trinchieri, Giorgio
- Segata, Nicola
- Kroemer, Guido
- Venue
- Nature Medicine
- Published
- 2025-04
- Volume
- 31
- Issue
- 4
- Pages
- 1085-1098
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4409370702
- Cited by
- 23
- References
- 104
- Citations by year
- 2026: 13 · 2025: 10
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Seerave Foundation (825410)
- European Commission (825410, HORIZON2020)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, tumor microbiome, dysbiosis, intestinal permeability, intestinal metabolism, antitumor immunity, tumor surveillance, antibiotic-induced dysbiosis, proton pump inhibitors, clinical translation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Neoplasms, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of the ONCOBIOME network in cancer microbiome research. https://app.cochat.ai/papers/10.1038/s41591-025-03608-8
- The paper
- Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., Boleij, A., Bol, K., Brusselaers, N., Budinska, E., Caldas, C., Cordero, F., Cremolini, C., Daillère, R., Denkert, C., . . . Kroemer, G. (2025). Impact of the ONCOBIOME network in cancer microbiome research. Nature Medicine. https://doi.org/10.1038/s41591-025-03608-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.